Drugs / Hyperpolarized Pyruvate (13C)
Hyperpolarized Pyruvate (13C)
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04656431 | Jun 2021 → Mar 2027 expected | primary central nervous system lymphoma | James Rubenstein | Recruiting | No outcome recorded |
| Phase 1 | NCT01229618 | Oct 2010 → Nov 2011 | prostate cancer | University of California, San Francisco | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hyperpolarized Pyruvate (13C) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01229618 ↗ |
| Modality | Diagnostic / imaging agent | “This phase I trial evaluates the feasibility of using hyperpolarized carbon C 13 pyruvate magnetic resonance imaging (MRI) in diagnosing patients with primary central nervous...” NCT04656431 ↗ |
| Route | Intravenous | “single hyperpolarized pyruvate IV (intravenous) injection” NCT01229618 ↗ |